Home / Resource Library / Orelabrutinib and MIL62 Combination Therapy Well Tolerated for Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaOrelabrutinib and MIL62 Combination Therapy Well Tolerated for Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma ESMO 2021